As of June 30, 2025, the Company had cash and cash equivalents of $56.1 million, compared to $69.8 million as of December 31, 2024. The Company’s guidance remains unchanged, and it continues to expect, based on current operational plans, that its existing cash and cash equivalents balance will enable it to fund its currently committed clinical trials, operating expenses, and capital expenditure requirements into 2027. This guidance does not include any payments associated with a potential partnership for alvelestat or business development activity around any of the Company’s non-core programs.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MREO:
- Mereo BioPharma’s Setrusumab Study: A Potential Breakthrough for Osteogenesis Imperfecta
- Mereo BioPharma’s Setrusumab Study Update: Implications for Investors
- Trump declares 50% tariff on copper, Brazil: Morning Buzz
- Mereo BioPharma price target lowered to $5 from $7 at Needham
- Mereo BioPharma’s Phase 3 Study Progresses Smoothly